Key result
Ivabradine lowers heart rate while sacubitril/valsartan cuts HFrEF mortality and hospitalizations, with unclear HFpEF benefit.
Why the study?
Do Ivabradine and Sacubitril/Valsartan improve clinical outcomes in patients with heart failure?
Do Ivabradine and Sacubitril/Valsartan improve clinical outcomes in patients with heart failure?
Sacubitril/Valsartan and Ivabradine offer significant, guideline-supported benefits in heart failure management, particularly for HFrEF and patients with elevated heart rates, respectively, though therapy must be individualized based on patient profiles.
This review provides a comprehensive analysis of two prominent heart failure treatments, Ivabradine and Sacubitril/Valsartan, highlighting their distinct mechanisms and clinical efficacy. Ivabradine primarily reduces heart rate by inhibiting the funny current in the sinoatrial node, offering benefits particularly in chronic heart failure patients with elevated heart rates. On the other hand, Sacubitril/Valsartan, an ARNI, has shown significant benefits in reducing mortality and hospitalization rates in heart failure with reduced ejection fraction (HFrEF), but its effects in HFpEF and HFmrEF are less conclusive. While Sacubitril/Valsartan offers a ground-breaking approach in heart failure treatment, it also presents an increased risk of hypotension. This review suggests that the choice of therapy should be tailored to individual patient profiles to optimize outcomes in heart failure management.
No takes yet. Share an insight, caveat, or question.
Choudhary et al. (2024) conducted a review in Heart failure. Ivabradine and Sacubitril/Valsartan was evaluated. Ivabradine effectively reduces heart rate in patients with elevated heart rates, while Sacubitril/Valsartan significantly reduces mortality and hospitalizations in HFrEF, with less conclusive benefits in HFpEF and HFmrEF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: